fashion -WSS

fashion

author：leisure time 2025-10-01 20:15:18 - browse：96

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Medicare inequities exacerbate Puerto Rico’s health disparities

WSS

A new nitrogen execution bill also undermines medical licensing

Medicare inequities exacerbate Puerto Rico’s health disparities

Antivenom research: Lessons from HIV applied in search for universal antidote

6 phony surgeries that take placebo to the extreme

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Artificial intelligence use in health care faces greater scrutiny in 2024

leisure time

fashion

leisure time

Drug repurposing or repositioning? The language matters

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Latigo launches with $135 million for Vertex

Heart attack and stroke risk calculators need revising

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Medicare details structure of new drug price negotiation program

Alabama hospital puts IVF treatments on hold

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Community Health Systems hospitals under DOJ investigation

leisure time

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Dario to buy mental health app maker Twill in cash and stock deal

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Doctors on social media are being harassed and cyberbullied

STAT Boddities: What happens to the brain when we get scared?

explore

focus

explore

focus